Polen Capital acquired 13.9k Hims & Hers Health shares worth $675k. That's 0.00% of their equity portfolio (168th largest holding). The stake costed the investor $632k, netting the investor a gain of 6.9% so far.
I expect price sensitive consumers to flood the market for compounded GLP-1 drugs before the 60-day FDA grace period for semaglutide compounders. HIMS projec...
Hims & Hers Health (NYSE: HIMS ) stock is taking a tumble after Hunterbrook Media released a short report on the telehealth company. Hunterbrook operates an ...
Spruce Capital Management issued a short report on Hims & Hers Health, Inc., but the call only forecast downside risk to $5. Read more about HIMS stock here.
According to Benzinga Pro data, during Q4, Hims & Hers Health (NYSE: HIMS ) posted sales of $167.20 million. Earnings were up 42.11%, but Hims & Hers Health ...